日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

帕博利珠单抗联合阿扎胞苷进行表观遗传修饰可重塑铂耐药性上皮性卵巢癌的肿瘤微环境:一项 II 期非随机临床试验

Landon, Blair V; Boland, Julia L; Wahner Hendrickson, Andrea E; Armstrong, Deborah K; Winterhoff, Boris; Wehr, Jaime; Annapragada, Akshaya V; Cherry, Christopher; Balan, Archana; Kaleka, Guneet; Velculescu, Victor E; Baylin, Stephen B; Zahnow, Cynthia A; Slamon, Dennis J; Konecny, Gottfried E; Anagnostou, Valsamo; Glaspy, John A

Leveraging ChatGPT for improved decision-making in interfacility transfers for plastic surgery emergencies based on United States guidelines

利用 ChatGPT 根据美国指南改进整形外科急症院间转诊决策

Hinson, Chandler; Allam, Omar; Glaspy, Jasmine; Kim, Trudy S; Ayyala, Haripriya

Patient-reported discordance between care goals and treatment intent in advanced cancer

晚期癌症患者自述的护理目标与治疗意图之间的不一致

Shah, Manan P; Wenger, Neil S; Glaspy, John; Hays, Ron D; Sudore, Rebecca L; Rahimi, Maryam; Gibbs, Lisa; Anand, Sidharth; Tseng, Chi-Hong; Walling, Anne M

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

一项针对晚期实体恶性肿瘤患者的 LHC165 单药治疗及联合 spartalizumab 治疗的 I 期临床试验

Curigliano, G; Jimenez, M M; Shimizu, T; Keam, B; Meric-Bernstam, F; Rutten, A; Glaspy, J; Schuler, P J; Parikh, N S; Ising, M; Hassounah, N; Wu, J; Leyk, M; Chen, X; Burks, H; Chaudhury, A; Otero, J; Cabanas, E Garralda

Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial

在接受骨髓毒性化疗的乳腺癌女性患者中,依非格司亭α在提供中性粒细胞支持方面不劣于培非格司亭:一项2期随机、多中心、开放标签试验的结果

Glaspy, John; Bondarenko, Igor; Krasnozhon, Dmitrii; Rutty, Dean; Chen, Jianmin; Fu, Yanyan; Wang, Shufang; Hou, Qingsong; Li, Simon

Gallstone ileus causing perforation of multiple segments of small bowel

胆石性肠梗阻导致多段小肠穿孔

Eiref, Andrew D; Hester, Karri; Glaspy, Tyler; Sarkisova, Anna; Anand, Sohini; Zimmerman, Patrick W; Nicoara, Michael; Patel, Krishan; Walden, Heath; Eiref, Simon D

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

Talimogene laherparepvec联合ipilimumab对比ipilimumab单药治疗晚期黑色素瘤:一项多中心、随机、开放标签II期试验的5年最终分析

Chesney, Jason A; Puzanov, Igor; Collichio, Frances A; Singh, Parminder; Milhem, Mohammed M; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore; Hauschild, Axel; Lebbé, Celeste; Joshi, Harshada; Snyder, Wendy; Mehnert, Janice M

Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors

抗体药物偶联物CLDN6-23-ADC治疗CLDN6阳性实体瘤的临床前疗效

Martina S J McDermott ,Neil A O'Brien ,Benjamin Hoffstrom ,KeWei Gong ,Ming Lu ,Jun Zhang ,Tong Luo ,Min Liang ,Weiping Jia ,Jenny J Hong ,Kevin Chau ,Simon Davenport ,Bin Xie ,Michael F Press ,Richard Panayiotou ,Abram Handly-Santana ,Joan S Brugge ,Leonard Presta ,John Glaspy ,Dennis J Slamon

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

TRIO-15 是一项多中心、开放标签的 II 期研究,旨在评估加尼妥单抗治疗复发性铂敏感卵巢癌患者的疗效和安全性。

Davidson, T M; Lebreton, C L; Hendricksen, A E Wahner; Atkinson, H J; Larson, M C; Oberg, A L; Provencher, D M; Glaspy, J A; Karlan, B Y; Slamon, D J; Konecny, G E; Ray-Coquard, I L

A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer

一项针对HER2阴性乳腺癌的新辅助治疗方案——纳武利尤单抗、伊匹木单抗联合病灶内溶瘤病毒疗法的初步研究

Nguyen, Vina P; Campbell, Katie M; Nowicki, Theodore S; Elumalai, Nila; Medina, Egmidio; Baselga-Carretero, Ignacio; DiNome, Maggie L; Chang, Helena R; Oseguera, Denise K; Ribas, Antoni; Glaspy, John A